Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2001
The purpose of this study is to evaluate both the efficacy and toxicity of infusional arsenic trioxide in the treatment of patients with relapsed or refractory acute promyelocytic leukemia (APML). In addition, correlation between pharmacokinetic data and both therapeutic response and therapy-related toxicities will be sought.
Epistemonikos ID: 496fe09af6b172c822a54130b2de1da75d56e1a7
First added on: Jan 21, 2022